Investment, Funding & Disinvestments
-
Aspen Pharmacare agrees to US$220M Ovestin deal as it refocuses on emerging markets
Ennogen, which focuses on European markets, will acquire the rights and intellectual property, while Aspen will retain a manufacturing and supply role under long-term agreements.
-
RMHC expands Mother’s Lodge at South Africa’s Chris Hani Baragwanath Hospital
The nearly R20 million (US$1.20 million) development will increase the facility’s capacity from 15 bedrooms accommodating 30 mothers to 36 bedrooms serving 72 mothers.
-
Vertex deploys Casgevy gene-editing platform across authorized NHS treatment hubs
The Medicines and Healthcare products Regulatory Agency (MHRA) approved the expanded indication, lowering the minimum eligible age from 12 to five years for both conditions.
-
Lonza expands ADC manufacturing capacity at its Visp site in Switzerland
Lonza also plans to introduce 500-litre single-use manufacturing capacity across its existing mid-scale bioconjugation facilities from 2027.
-
AstraZeneca launches US$1.5B restructuring programme to fund pipeline growth through 2029
AstraZeneca plans to reinvest most of the savings in research and development, although the programme is expected to incur up to US$2 billion in one-time restructuring costs over three years.
-
Dren Bio raises US$350M to advance dibotatug towards late-stage clinical development
The clinical-stage biotechnology company will also use the proceeds to expand its research pipeline across autoimmune diseases, immunology, neurological disorders and oncology.
-
Bracco invests US$230M to build first US Contrast Media manufacturing plant in North Carolina
The new sterile manufacturing plant will complement Bracco’s existing production operations in Europe, Asia and Canada, expanding its global manufacturing network.
-
Glenmark Pharmaceuticals opens US Distribution Centre in Allentown
The facility operates in accordance with requirements established by the US Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA).
-
OMRON Healthcare begins full-scale blood pressure monitor production at first Indian factory
Operated by OMRON HEALTHCARE MANUFACTURING INDIA Pvt. Ltd., the approximately 24,000-square-metre factory is located at ORIGINS by Mahindra and has five production lines serving the Indian market.
-
WHO supports Malawi’s US$437.9M Global Fund funding request for 2027–2030
The proposal, developed under the Global Fund’s Grant Cycle 8 (GC8), seeks US$339.6 million for HIV, US$16.1 million for TB and US$82.2 million for malaria.